Masong, Harmelene C.
HRN: 10-67-36 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/24/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
11/24/2022
12/01/2022
IV
390mg
OD
Aml, Mucositis
Waiting Final Action
Indication: Empiric Type of Infection: BloodstreamEye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes